SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML
| Autor: | Courtney D. DiNardo, Marina Konopleva, Kapil Saxena, Naval Daver |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
Antineoplastic Agents Apoptosis Bcl-xL chemistry.chemical_compound hemic and lymphatic diseases medicine Humans MCL1 Protein Kinase Inhibitors biology Venetoclax business.industry Intrinsic apoptotic pathway Cytarabine Myeloid leukemia Hematology Bridged Bicyclo Compounds Heterocyclic Leukemia Myeloid Acute Oncology Hypomethylating agent chemistry biology.protein Cancer research business medicine.drug |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 22:133-139 |
| ISSN: | 2152-2650 |
| Popis: | The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in acute myeloid leukemia continues to be explored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect